Dynamic Tumor Resistance, Metastatic Colorectal Cancer
Conditions
Brief summary
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Detailed description
Primary Objectives * To determine differences in PFS based on differential response markers in paired tissue biopsies (Part I). * To improve progression-free survival with novel intervention strategies (Part II) Secondary Objectives * To collect serial tissue and blood biomarkers and efficacy data associated with standard of care or investigational therapy across multiple lines of therapy. * To determine the overall response rate (ORR), and overall survival (OS) based on the presence of specific biomarkers or adaptive interventions.
Interventions
Blood draws, biopsies, samples and MRI.
DRUGBevacizumab
Given by IV
DRUGCetuximab
Given by Iv
DRUGPanitumumab
Given by Iv
DRUGFOLFIRI
Given by Iv
DRUGFOLFOX
Given by Iv
DRUGEncorafenib
Given by po
DRUGAdagrasib
Given by Po
DRUGTrifluridine/tipiracil (TAS-102)
Given by po
DRUGTrastuzumab deruxtecan
Given by IV
DRUGTucatinib
Given by po
DRUGSotorasib
Given by po
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Eligibility Criteria * The participant has a histologically or cytologically confirmed diagnosis of colorectal cancer. * Confirmation of non-MSI-H/pMMR status. * Tumor that is measurable as per RECIST v1.1 and biopsy able, defined as lesion/tumor that can be biopsied without undue risk. * Age ≥ 18 years. * ECOG performance status 0-2. * Due to the potential teratogenic effect of chemotherapy, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for an adequate amount of time following end of treatment based on the SOC indications for the administered regimen (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following: * Postmenopausal (no menses in greater than or equal to 12 consecutive months). * History of hysterectomy or bilateral salpingo-oophorectomy. * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). * History of bilateral tubal ligation or another surgical sterilization procedure. * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for an adequate amount of time following end of treatment based on the SOC indications for the administered regimen. * The participant is willing and able to sign the informed consent in compliance with protocol requirements, including mandatory biopsies.
Exclusion criteria
* Pregnancy. * Participants with concurrent or recent (less than 1 year before consent) malignancies that have the potential to interfere with the study safety and/or endpoint assessments will be excluded. * Participants for whom there is an intent to proceed to curative therapy (i.e., resection) will be excluded. * Participants who have undergone treatment with both oxaliplatin and irinotecan in the metastatic setting will be excluded. Treatment with oxaliplatin in the adjuvant setting with relapse within 6 months will be counted as treatment in the metastatic setting for the purpose of this criterium. * For participants who have undergone treatment for metastatic disease, participants who have not progressed (clinically or radiographically) on the most recent therapy will be excluded. * Concurrent participation in any other interventional trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| safety and adverse events (AEs) | Through study completion; an average of 1 year | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Countries
United States
Contacts
CONTACTScott Kopetz, MD
PRINCIPAL_INVESTIGATORScott Kopetz, MD
M.D. Anderson Cancer Center
Outcome results
None listed